ModAstera Inc. and Taiwan's Wellgen Medical Form Strategic Partnership
NQ Score
0/100
N1 Content Completeness
90
AI Summary (NQ-processed)
ModAstera Inc., a Tokyo-based medical AI platform company, announced a strategic partnership with Taiwan-based Wellgen Medical CO., LTD to jointly develop an AI screening model for cancer cytopathology, combining Wellgen Medical's FDA-cleared tomographic imaging technology with ModAstera's medical AI development platform. This collaboration aims to address the global shortage of pathologists and improve diagnostic accuracy, particularly for metastatic cancer cells in body fluid cytopathology.